|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 4/30/20 Idexx Laboratories Inc/DE 10-Q 3/31/20 101:9.4M |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 1.23M
2: EX-10.1 Material Contract HTML 31K
3: EX-10.2 Material Contract HTML 35K
4: EX-31.1 Certification -- §302 - SOA'02 HTML 35K
5: EX-31.2 Certification -- §302 - SOA'02 HTML 35K
6: EX-32.1 Certification -- §906 - SOA'02 HTML 30K
7: EX-32.2 Certification -- §906 - SOA'02 HTML 30K
21: R1 Cover Page HTML 80K
79: R2 Condensed Consolidated Balance Sheets HTML 142K
90: R3 Condensed Consolidated Balance Sheets HTML 41K
(Parenthetical)
56: R4 Condensed Consolidated Statements of Income HTML 97K
20: R5 Condensed Consolidated Statements of Comprehensive HTML 69K
Income
78: R6 Condensed Consolidated Statements of Comprehensive HTML 39K
Income (Parenthetical)
89: R7 Condensed Consolidated Statements of Stockholders' HTML 62K
Equity (Deficit)
51: R8 Condensed Consolidated Statements of Stockholders' HTML 29K
Equity (Deficit) (Parenthetical)
22: R9 Condensed Consolidated Statements of Cash Flows HTML 113K
15: R10 Basis of Presentation and Principles of HTML 38K
Consolidation
48: R11 Accounting Policies HTML 34K
80: R12 Revenue Recognition HTML 118K
67: R13 Acquisitions HTML 31K
16: R14 Share-Based Compensation HTML 44K
49: R15 Credit Losses HTML 37K
81: R16 Inventories HTML 38K
68: R17 Leases HTML 51K
17: R18 Other Current and Long-Term Assets HTML 55K
47: R19 Accrued Liabilities HTML 48K
100: R20 Debt HTML 93K
64: R21 Repurchases Of Common Stock HTML 49K
35: R22 Income Taxes HTML 31K
42: R23 Accumulated Other Comprehensive Income HTML 105K
101: R24 Earnings Per Share HTML 47K
65: R25 Commitments, Contingencies and Guarantees HTML 33K
36: R26 Segment Reporting HTML 145K
43: R27 Fair Value Measurements HTML 112K
99: R28 Hedging Instruments HTML 102K
66: R29 Subsequent Events (Notes) HTML 30K
71: R30 Accounting Policies (Policies) HTML 76K
84: R31 Revenue Recognition (Tables) HTML 60K
46: R32 Share-Based Compensation (Tables) HTML 40K
14: R33 Inventories (Tables) HTML 39K
70: R34 Leases (Tables) HTML 47K
83: R35 Other Current and Long-Term Assets (Tables) HTML 57K
45: R36 Accrued Liabilities (Tables) HTML 49K
13: R37 Debt (Tables) HTML 85K
69: R38 Repurchases of Common Stock (Tables) HTML 49K
85: R39 Accumulated Other Comprehensive Income (Tables) HTML 106K
61: R40 Earnings Per Share (Tables) HTML 47K
95: R41 Segment Reporting (Tables) HTML 143K
41: R42 Fair Value Measurements (Tables) HTML 101K
32: R43 Hedging Instruments (Tables) HTML 85K
60: R44 Accounting Policies (Details) HTML 44K
94: R45 Revenue Recognition (General Narrative) (Details) HTML 32K
40: R46 Revenue Recognition (Lease Revenue) (Details) HTML 29K
31: R47 Revenue Recognition (Extended Warranties and HTML 43K
Post-Contract Support) (Details)
59: R48 Revenue Recognition (Remaining Performance HTML 73K
Obligation) (Details)
96: R49 Revenue Recognition (SaaS Subscriptions) (Details) HTML 30K
87: R50 Revenue Recognition (Up-Front Customer Loyalty HTML 33K
Programs) (Details)
72: R51 Revenue Recognition (Volume Commitment Programs) HTML 38K
(Details)
26: R52 Revenue Recognition (Instrument Rebate Programs) HTML 33K
(Details)
57: R53 Revenue Recognition (Reagent Rental Programs) HTML 40K
(Details)
88: R54 Revenue Recognition (Disaggregation of Revenue by HTML 54K
Major Product and Service Categories) (Details)
73: R55 Revenue Recognition (Disaggregation of Revenue by HTML 40K
Principal Geographic Area, Based on Customers'
Domiciles) (Details)
27: R56 Revenue Recognition (Costs to Obtain a Contract) HTML 38K
(Details)
58: R57 Acquisitions Acquisitions (Details) HTML 44K
86: R58 Share-Based Compensation (Narrative) (Details) HTML 38K
74: R59 Share-Based Compensation (Assumptions Used) HTML 39K
(Details)
28: R60 Credit Losses (Details) HTML 41K
38: R61 Inventories (Details) HTML 38K
97: R62 Leases (Maturities of Operating Lease Liabilities) HTML 56K
(Details)
62: R63 Leases (Narrative) (Details) HTML 37K
29: R64 Leases (Supplemental Cash Flow Information) HTML 31K
(Details)
39: R65 Other Current and Long-Term Assets (Schedule Of HTML 45K
Other Current Assets) (Details)
98: R66 Other Current and Long-Term Assets (Schedule Of HTML 47K
Other Long-term Assets) (Details)
63: R67 Accrued Liabilities (Schedule Of Accrued HTML 43K
Liabilities) (Details)
30: R68 Accrued Liabilities (Schedule Of Other Long-term HTML 35K
Liabilities) (Details)
37: R69 Debt Debt (Schedule of Current Senior Notes HTML 64K
Outstanding) (Details)
53: R70 Debt Debt (Narrative) (Details) HTML 57K
24: R71 Repurchases of Common Stock (Details) HTML 47K
76: R72 Income Taxes (Details) HTML 30K
92: R73 Accumulated Other Comprehensive Income (Schedule HTML 57K
Of AOCI) (Details)
52: R74 Accumulated Other Comprehensive Income (Schedule HTML 42K
of Reclassifications out of AOCI) (Details)
23: R75 Earnings Per Share (Schedule Of Reconciliation Of HTML 38K
Shares Outstanding For Basic And Diluted Earnings
Per Share) (Details)
75: R76 Earnings Per Share (Schedule Of Number Of HTML 34K
Anti-Dilutive Stock Options) (Details)
91: R77 Segment Reporting - Allocated Costs (Details) HTML 73K
55: R78 Segment Reporting - Summary of Segment Performance HTML 68K
(Details)
18: R79 Fair Value Measurements (Narrative) (Details) HTML 33K
54: R80 Fair Value Measurements (Schedule of Assets and HTML 73K
Liabilities) (Details)
25: R81 Hedging Instruments (Narrative) (Details) HTML 61K
77: R82 Hedging Instruments (Derivatives Designated In HTML 35K
Cash Flow Hedging Relationships) (Details)
93: R83 Hedging Instruments (Schedule Of Fair Values And HTML 66K
Balance Sheet Classifications Of Derivatives
Designated As Hedging Instruments) (Details)
50: R84 Subsequent Events (Details) HTML 39K
34: XML IDEA XML File -- Filing Summary XML 187K
19: XML XBRL Instance -- idxx2020q110-q_htm XML 2.35M
33: EXCEL IDEA Workbook of Financial Reports XLSX 98K
9: EX-101.CAL XBRL Calculations -- idxx-20200331_cal XML 269K
10: EX-101.DEF XBRL Definitions -- idxx-20200331_def XML 631K
11: EX-101.LAB XBRL Labels -- idxx-20200331_lab XML 1.57M
12: EX-101.PRE XBRL Presentations -- idxx-20200331_pre XML 1.00M
8: EX-101.SCH XBRL Schema -- idxx-20200331 XSD 172K
44: JSON XBRL Instance as JSON Data -- MetaLinks 370± 540K
82: ZIP XBRL Zipped Folder -- 0000874716-20-000018-xbrl Zip 306K
| Exhibit |
1) | I
have reviewed this report on Form 10-Q for the quarter ended March 31, 2020 of IDEXX Laboratories, Inc.; |
2) | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3) | Based
on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4) | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b) | Designed
such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report, based on such evaluation;
and |
d) | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting;
and |
5) | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
a) | All
significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Date:
April 30, 2020 | |
| |
| President and Chief Executive Officer |
| (Principal Executive Officer) |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 4/30/20 | 8-K | ||
| For Period end: | 3/31/20 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 2/22/24 IDEXX Laboratories, Inc. 10-K 12/31/23 140:15M 2/16/23 IDEXX Laboratories, Inc. 10-K 12/31/22 136:15M 2/16/22 IDEXX Laboratories, Inc. 10-K 12/31/21 151:18M 2/12/21 IDEXX Laboratories, Inc. 10-K 12/31/20 131:15M |